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ABSTRACT
The glomerular podocytes form a major size selective barrier for the filtration of serum proteins and reduced podocyte number is a critical event
in the pathogenesis of proteinuria during diabetic nephropathy (DN). An elevated level of growth hormone (GH) is implicated as a causative
factor in the development of nephropathy in patients with type 1 diabetes mellitus. We have previously shown that podocytes express GH
receptor and are a target for GH action. To elucidate the molecular basis for the effects of GH on podocyte depletion, we conducted PCR-array
analyses for extracellular matrix and adhesion molecules in podocytes. Our studies reveal that GH increases expression of a gene that encodes
transforming growth factor-beta-induced protein (TGFBIp) expression. Similarly, microarray data retrieved from the Nephromine database
revealed elevation of TGFBIp in patients with DN. Treatment with GH results in increased secretion of extracellular TGFBIp by podocytes. Both
GH and TGFBIp induced apoptosis and epithelial mesenchymal transition (EMT) of podocytes. Exposure of podocytes to GH and TGFBIp resulted
in increased migration of cells and altered podocyte permeability to albumin across podocyte monolayer. Administration of GH to rats induced
EMT and apoptosis in the glomerular fraction of the kidney. Therefore, we conclude that the GH-dependent increase in TGFBIp in the podocyte is
one of the mechanisms responsible for podocyte depletion in DN. J. Cell. Biochem. 116: 1947–1956, 2015. © 2015 Wiley Periodicals, Inc.
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Diabetic nephropathy (DN), characterized by increased glo-merular permeability to serum proteins, is the most common
cause of end-stage renal disease (ESRD) [Kumar et al., 2013]. The
three components; fenestrated endothelium of glomerular capil-
laries, the glomerular basement membrane (GBM), and the visceral
glomerular epithelial cells (podocytes) constitute the glomerular
filtration apparatus, which is permeable to water and small dissolved
solutes and offers size selective filtration for the larger molecules
[Anil Kumar et al., 2014]. Podocytes are terminally differentiated
epithelial cells that regulate glomerular permselectivity, synthesize
components of GBM, and counteract the intraglomerular hydrostatic
pressure. Podocytes form interdigitating foot processes with
bridging slit-diaphragms to regulate renal ultra-filtration and
prevent loss of high molecular weight serum proteins into urine.
Normal renal filtration is dependent on the integrity of interaction
between podocyte and GBM and an adequate number of podocytes
[Anil Kumar et al., 2014]. Podocyte depletion is considered as a
hallmark of glomerular diseases including DN [Anil Kumar et al.,
2014; Nakamura et al., 2000; Shankland, 2006]. Podocyte depletion
could be the result either apoptosis and/or podocyte detachment
from the GBM [Wolf et al., 2005]. Human biopsy studies indicate that
podocytes are injured very early in the pathogenesis of DN
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[Wolf et al., 2005]. Decreased expression of podocyte proteins such
as nephrin and podocin has been documented in experimental
models of nephropathy [Aaltonen et al., 2001]. Although several
mechanisms that result in podocyte damage in DN have been
proposed, a complete understanding of the molecular and cellular
mechanism(s) mediating podocyte loss in DN is lacking.
The pathogenesis of DN is complex and an array of factors have
been suggested as potential contributors to podocyte damage in
diabetes mellitus [Anil Kumar et al., 2014]. One of the axis that
have been implicated in DN is the GH-IGF1 axis [Christiansen
et al., 1981; Cummings et al., 1998; Kumar et al., 2011].
Progression to ESRD is associated with abnormalities in pituitary
growth hormone (GH) secretion and diminished renal clearance of
GH [Tonshoff et al., 1995]. Children with ESRD have an increased
number of secretory bursts of GH compared to children with
normal renal function [Tonshoff et al., 1995]. Definite evidence for
a causal role of GH in nephropathy has come from acromegalic
subjects wherein excess GH levels were associated with significant
structural and functional changes in the kidney and albuminuria
[Baldelli et al., 2008; Manelli et al., 2000]. In case of mice
transgenic for bovine GH, glomeruli was disproportionately
enlarged paralleled with glomerulosclerosis and increased albu-
min: creatinine ratio [Doi et al., 1990]. Experimental animals with
hyperactivity of the GH-axis exhibit podocyte damage and poor
renal function [Kumar et al., 2011]. In contrast, GH-deficient dwarf
rats had minimal proteinuria, mild renal functional impairment
and moderate renal histological scarring [El Nahas et al., 1991]. In
our earlier studies, we demonstrated that podocytes express the GH
receptor [Reddy et al., 2007] and respond to GH by inducing the
expression of ZEB2 that results in decreased expression of P- and
E-cadherins [Kumar et al., 2010].
One of the abnormalities from patients with diabetes mellitus is
loss of podocytes [Verzola et al., 2007]. The urinary sediments
from patients with proteinuric diseases including DN contain
increased levels of podocyte markers [Sato et al., 2009; Kalani
et al., 2013]. Interaction between podocytes and GBM is critical to
the normal renal filtration since podocytes anchor to GBM and
regulate glomerular permselectivity. Perturbations in various
components of extracellular matrix (ECM) are associated with
DN [Mason and Wahab, 2003; Kolset et al., 2012]. However, the
effect of GH on cell-adhesion and ECM components that determine
podocyte-GBM integrity is unclear. In this study we investigated
the effect of GH on expression of ECM and adhesion molecules of
podocytes. Gene expression profiling of mouse podocytes by PCR-
array identified GH dependent up-regulation of transforming
growth factor-beta-induced protein (TGFBIp). TGFBIp is also
known as beta induced gene human clone 3 (BIGH3) and is a 68-
kDa extracellular matrix protein and it has been postulated to be
involved in cell-matrix interaction and cell migration [Bae et al.,
2002; Kim et al., 2003b]. In a recent study, it was reported that
TGFBIp promotes metastasis of colon cancer by enhancing cell
extravasation [Ma et al., 2008]. TGFBIp also mediates TGFb-
evoked apoptosis [Zamilpa et al., 2009]. It is considered that
TGFBIp elicits both epithelial mesenchymal transition (EMT) and
apoptosis. Our present study indicates a role for TGFBIp in
transducing the effect of GH on the podocytes.
MATERIALS AND METHODS
CULTURING OF PODOCYTES
Conditionally immortalized mouse podocyte (MPC-5) cells were
maintained under growth-permissive conditions at 33°C and 5%
CO2. RPMI-1640 medium containing 10% FBS, 100 units/ml of
penicillin, 100mg/ml of streptomycin, and 10 units/ml of mouse g-
interferon (Sigma) were used to maintain MPC-5 cells in proliferat-
ing condition. To induce differentiation, podocytes were shifted to
non-permissive conditions at 37°C without g-interferon for 10 days.
Differentiated podocytes were maintained for 12–16 h in serum-free
medium before treating with hGH (Pfizer) or pegvisomant (Pfizer) or
rTGFBIp (R&D Systems).
PCR-ARRAY ANALYSIS
MPC-5 cells were harvested after 48 h of treatment with or without
GH (500 ng/ml). Total RNA was isolated, purified using RNeasy kit
(QIAGEN) and subjected to first-strand cDNA synthesis. The
expression of 84 genes associated with ECM and adhesion molecules
was profiled using cDNA isolated from podocytes employing RT2
Profiler PCR Array (http://www.sabiosciences.com/genetable.php?
pcatn¼PAMM-013A). The protocol and data analysis were per-
formed according to manufacturer’s instructions.
REAL-TIME QUANTITATIVE PCR ASSAY
Total RNA was extracted and purified fromMPC-5 cells treated with
or without GH (500 ng/ml) or TGFBIp (5mg/ml). Quantitative PCR
was performed using QuantiTect SYBR Green RT-PCR kit (QIAGEN)
with 7000 Prism detection system (ABI). mRNA expression of each
gene was normalized using the expression of GAPDH that was used
as an internal control.
ESTIMATION OF TGFBIP BY ELISA
GH dependent secretion of TGFBIp was estimated by stimulating
podocytes with GH (500 ng/ml) for varying time periods ranging
from 12–48 h. Spent culture media from podocytes exposed to GH
was collected at each time point and centrifuged at 200 g for 5min
at 4°C. Supernatants so obtained were used to measure TGFBIp using
sandwich-ELISA with mouse monoclonal antibody against TGFBIp
(R&D Systems) as a capture antibody and biotinylated goat antibody
against TGFBIp (R&D Systems) as the detection antibody. Strepta-
vidin-horseradish peroxidases followed by o-phenylenediamine
dihydrochloride were added to initiate the color reaction and the
reactions were then stopped with sulfuric acid and read at 490 nm.
Recombinant human TGFBIp was used as a standard.
WHOLE CELL LYSIS AND IMMUNOBLOTTING
MPC-5 cellswere treatedwith orwithoutGHorTGFBIp for specified time
periods. Cellswerewashedwith ice-coldPBSand lysedusing1Xcell lysis
(RIPA) buffer supplemented with protease inhibitor mixture (Roche). Cell
lysate was subjected to centrifugation at 12000 g for 15min to collect
the supernatant, which was processed for SDS-PAGE and immunoblot-
ting. All antibodies used in this study were procured from cell-signaling
technologies and used in 1:1,000 dilutions. When indicated, the
membrane was then stripped and reblotted with anti-tubulin antiserum
(Sigma; 1:1,000) to verify equality of sample loading.
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CELL DEATH ANALYSIS
For cell death analysis, podocytes were treated with GH for varying
period of time ranging from 12–72 h. At each time point, the floating
and attached cells were harvested and used for the enumeration of
viable andnonviable cells. Cellswere reconstituted in freshmedia and
an equal volume of trypan blue (0.4%) solution was added. Cells were
counted using hemocytometer and light microscope. The number of
viable (unstained) cells and nonviable (stained) cells were enumerated
and expressed as a percentage of total number of cells (always 500
cells) counted. TUNEL assay (ApoAlert; Clontech) was performed to
determine the apoptosis of MPC-5 cells treated with GH or TGFBIp.
Podocyteswere cultured on cover slips and treatedwithGHor TGFBIp
for indicated time periods. Cells were washed with PBS andfixedwith
4% formaldehyde for 25min at 4°C, permeabilized with 0.2% Triton
X-100 for 5min on ice, and incubated with a mixture of nucleotides
and TdT enzyme for 60min at 37°C in humidified chamber. Reaction
was terminated with a solution containing 300mM sodium chloride
and 30mM sodium citrate, and the cover slips were mounted on glass
slides. Apoptotic nuclei were detected under fluorescence microscope
with characteristic morphology of nuclear fragmentation and nuclear
condensation. A total of 100 cells were counted for each sample.
Results were expressed as the percentage of apoptotic cells. Detection
of caspase-3 activity was performed with ApoAlert Caspase
Colorimetric Assay Kit (Clontech). Differentiated podocytes were
treated with or without TGFBIp and harvested. Equal number of cells
were resuspended in lysis buffer and centrifuged at 12,0008 g for
10min at 4°C. Supernatantwas collected and incubatedwith caspase-
3 substrate Acetyl-DEVD-p-nitroaniline (50mM) at 37°C for 1 h; and
the absorbance was measured at 405nm.
SCRATCH ASSAY
Mouse podocytes were seeded in 6 well plates and grown under
normal growth conditions to reach upto 95% confluence. When the
cells are ready, media was aspirated and a scratch was made using a
pipette tip. The scratch should bemade in the form of “þ” in a smooth
sweeping motion. Cells were washed twice with pre-warmed media
in order to remove any debris from damaged cells. Images of cells
were taken before and after treating with GH or TGFBIp at a regular
time points to monitor the rate at which the denuded area of cells get
colonized by the surrounding migrating cells. The area covered by
cells is quantified using Image J software (NIH, Bethesda, MD) and
represented as the percent area coverage (Cell Area/ROI Area 100).
Fig. 1. GH dependent expression of TGFBIp in glomerular podocytes. A: Differentiated mouse podocytes (MPC-5 cells) were treated with or without GH for 48 h, RNA was
isolated and PCR-array (Qiagen #PAMM-013) was performed and heat map was obtained. B: Outline of PCR-array plate. G3 well indicates expression of TGFBI C: Expression of
TGFBIp transcript in podocytes treated with GH (500 ng/ml) for indicated time periods. The data are depicted as mean SE and *denotes expression of TGFBIp under GH stimulus
were different from that under control conditions with P< 0.05; n¼ 5. D: A representative immunoblot for TGFBIp and tubulin from podocytes treated with GH (500 ng/ml) for
the indicated time periods. E: Densitometric quantification of TGFBIp expression normalized to tubulin. Data are means SE of three times experiments, *,P< 0.05.
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ALBUMIN INFLUX ASSAY
MPC-5 cells were plated on a 12-well plate and differentiated at
nonpermissive conditions as described above by culturing for 10
days. The cells were then treated with either GH (500 ng/ml) or
TGFBIp (5mg/ml) for 24 h essentially as described earlier [Han
et al., 2010]. Subsequently, the medium was removed, and cells
were washed twice with a 1mM CaCl2 and 1mM MgCl2 mixture to
preserve cadherin junctions. Two milliliters of RMPI 1640 medium
with 40mg/ml BSA was then placed in the bottom chamber, and
0.3ml of RPMI 1640 medium (without albumin) was placed in the
top chamber. The cells were incubated at 37°C, aliquots of medium
were collected from the top chamber at various (1-, 2-, and 4-h)
time points, and albumin concentration was measured in these
aliquots using the bicinchoninic acid protein assay kit (Sigma–
Aldrich).
ANIMAL EXPERIMENT
Expression of EMTmarkers was examined in glomeruli isolated from
rats injected with GH. Adult female Wistar rats (body weight 200 g)
were used in this study. Individual rats were housed in a cage and
placed in a pathogen free facility with a 12:12 h artificial light cycle.
Temperature and humidity were kept in a controlled range. The
animals had free access to standard chow and drinking water
throughout the experiment. Experimental rats (n¼ 6) received a
single i.p dose of hGH 1.5mg/kg/day for two weeks whereas control
rats (n¼ 6) have received an equal volume of saline. Prior to
sacrificing, the animals were placed in individualmetabolic cages for
determination of 24-h urine volume, glucose, creatinine and
albumin. For histopathology assessment, kidneys were perfused
and fixed with alternating intra-aortic injections of PBS (0.02M, pH
7.4) and 10% neutral-buffered formalin until blanching of kidneys
was achieved. All experimental procedures were approved by the
University of Hyderabad institutional Animal Care and Use
Committee.
KIDNEY LYSATE PREPARATION
Under general anesthetia, kidneys were perfused with PBS
containing 50U/ml sodium heparin through a cannula placed in
the abdominal aorta. Hydrostatic pressure during perfusion was kept
constant at 100mmHg and perfusion was carried out till the kidneys
were blanched. Following perfusion with PBS, the left kidney was
ligated and the right kidney was perfused with 50ml of ferric oxide
slurry in PBS via the abdominal aorta. The right kidney with iron-
containing glomeruli was minced and glomeruli isolated by a
technique modified from that of Meezan et al. Isolated glomeruli
were further subjected to homogenization with lysis buffer
containing protease inhibitors mixture and used for
immunoblotting.
IMMUNOHISTOCHEMICAL ANALYSIS
Both paraffin-embedded and cryosections of kidneys from control
and experimental rats were prepared. Paraffin-embedded sections
were deparaffinized with xylene and rehydrated through a
descending ethanol gradient. Hemotoxylin and eosin staining was
performed to examine the morphology. Immunostaining for WT-1
and synaptopodin (Santa Cruz Biotechnology, Dallas, TX) was
performed in paraffin embedded sections and cryosections,
respectively. The number of podocytes per glomerulus was
determined by counting the number of WT-1 expressing cells in
each glomerulus from paraffin sections. Each slide (15 glomeruli per
section and n¼ 5 per group) were observed independently by three
investigators blinded to the identity of the paraffin section.
Fig. 2. GH induces extracellular secretion of TGFBIp. A: Differentiated mouse podocytes were treated with GH for indicated time periods and spent culture media collected.
Clarified supernatant was used to estimate TGFBIp content by sandwich ELISA as described in methods. B: Meta-analysis of TGFBIp mRNA expression in glomeruli from healthy
living donor (n¼ 41) and DN patients (n¼ 12) using NephromineTM. Over expression gene rank 109 (top 1%); reporter 201506_at; P value: 4.02E-7; t-Test-6.325, and fold
change 2.934. Nephromine (Life Technologies, Ann Arbor, MI) was used for analysis and visualization.
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STATISTICAL ANALYSIS
Data are presented as mean SE. SPSS software (SPSS, Inc.) was
used to apply Mann–Whitney and Kruskal–Wallis nonparametric
tests to analyze statistical differences between the distributions of
two or multiple independent samples, respectively. P values 0.05
were considered significant.
RESULTS
GH INCREASES TGFBIP EXPRESSION IN PODOCYTES
We used PCR array analysis to conduct a survey of the effect of GH
on the expression of genes that encode ECM and adhesion molecules
in the podocytes. Expression of transforming growth factor-beta-
induced gene (TGFBI, also known as BigH3) was elevated with GH
treatment alongwith other members of ECM and adhesionmolecules
including collagen type IIa1, integrin E, laminin a3/b3, and MMP-3
(G3 well of Fig. 1A and B and Fig.S1A). The fold expression of all the
genes tested was provided in Table S1. TGFBI encodes for TGFBI-
protein (TGFBIp), which is also called Bigh3 protein or keratoepi-
thelin. Results obtained from PCR array analysis were confirmed
with quantitative real time RT-PCR measurement of the steady state
abundance of TGFBI mRNA. For this purpose, MPC-5 cells were
exposed to GH, and mRNA was harvested at various time periods.
These experiments revealed that levels of TGFBIp mRNA were
increased 1.5- (12 h), 1.9- (24 h), and 3.1-fold (48 h) following
exposure of podocytes to GH (Fig. 1C). Immunoblotting of lysates
from podocytes exposed to GH revealed time-dependent increase in
the levels of TGFBIp protein (Fig. 1D and E). Further, we have tested
whether this up-regulation of TGFBIp in podocytes was specific to
GH or not in the presence of GH receptor (GHR) antagonist,
pegvisomant. Pegvisomant ameliorated GH induced TGFBIp expr-
ession in podocytes (Fig. S1B). TGFBIp is an extracellular matrix
protein and secreted by cells. Therefore, we estimated TGFBIp levels
in spent culture media of podocytes that were exposed to GH.
Exposure of podocytes to GH resulted in an increased secretion of
TGFBIp with increased levels up to seven folds at 48 h of exposure
compared with cells that were na€ıve to GH treatment (Fig. 2A).
Fig. 3. GH and TGFBIp induce cell death. A: Differentiated mouse podocytes were treated with GH for indicated time periods. Cells were harvested and stained with trypan blue
and cell count was performed and data presented as % live cells versus dead cells. Differentiated mouse podocytes were treated with (B) either GH or (C) TGFBIp and TUNEL assay
was performed. TUNEL positive cells were counted and expressed as % of apoptotic cells. (%) Apoptotic cells¼ number of TUNEL positive staining cells/number of total cells
100% (at least 100 cells were counted for each sample). D: Caspase3 substrate assay was performed in mouse podocytes treated with TGFBIp and its activity was expressed in
relation to control. The data are depicted as mean SE. *denotes P< 0.05 (n¼ 5) for exposure to GH or TGFBIp vs control for the specified parameter.
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Further, we utilized the online database, www.nephromine.org that
provides curated data from genome-wide expression studies to
compare expression of TGFBIp in humans with DN. We identified
that expression of TGFBIp is higher in glomeruli from DN patients
compared to healthy donors (Fig. 2B).
GH INDUCES CELL DEATH IN PODOCYTES
As evidenced by PCR-array analysis and confirmed by RT-PCR and
immunoblotting, GH induces TGFBIp expression in podocytes. We
next investigated the consequence of GH dependent TGFBIp
expression in podocytes. Multiple evidences suggest that TGFBIp
induces cell death by apoptosis in a variety of cells including
retinal pericytes, CHO cells, and osteosarcoma cells [Kim et al.,
2003a; Zamilpa et al., 2009; Han et al., 2010]. We therefore studied
the effect of GH and TGFBIp on podocyte cell death. GH induced
time dependent cell death in podocytes (Fig. 3A). Following 12 h of
exposure to GH there was only a marginal decrease in viable cell
count, whereas 24 h, 48 h, and 72 h exposure to GH the percent of
live cells was decreased by 12%, 19%, and 35%, respectively (Fig.
3A). By employing TUNEL assay, we have confirmed the mode of
cell death in GH treated podocytes to be apoptosis (Fig. 3B).
Analogously, podocytes treated with TGFBIp also underwent
apoptosis and it was found that TGFBIp is more effective than GH
in inducing apoptosis of podocytes at concentrations tested (Fig.
3C). Increased activity of caspase-3 revealed that TGFBIp induced
cell death by apoptosis (Fig. 3D).
GH INDUCES EPITHELIAL MESENCHYMAL TRANSITION (EMT) IN
PODOCYTES
It has been posited that podocyte dedifferentiation and EMT could be
a potential mechanism resulting in podocyte dysfunction and
decreased count thus playing a causal role in the pathogenesis of
proteinuric diseases [Li et al., 2008]. TGFBIp promotes invasion of
tumor cells via EMT [Nummela et al., 2012; Ween et al., 2011].
Therefore, we assessed the expression of EMT markers in GH treated
podocytes and observed induction of ZEB2, which is known to play a
key role in EMT process (Fig. S2 A and B). In addition, we found that
exposure to GH resulted in decreased E-cadherin, increased N-
cadherin, and b-catenin expression (Fig. S2 A&B). Further, mRNA
analysis also revealed decreased E-cadherin, increased N-cadherin,
and b-catenin expression (Fig. S2C). In similar to GH treatment,
exposure of podocytes to TGFBIp also resulted in increased ZEB2, N-
cadherin, b-catenin, and decreased E-cadherin expression in
podocytes (Fig. 4A–C).
GH AND TGFBIP INDUCE PODOCYTE MIGRATION AND ALTER
FILTRATION BARRIER FUNCTION
To assess the functional consequence of effect of GH and TGFBIp on
podocytes, we examined whether these molecules induce migration
of podocytes employing a popular scratch assay. Our experiments
revealed that both GH and TGFBIp induce migration of cells and
TGFBIp is more effective than GH in inducing podocyte migration
(Fig. 5A and B). Furthermore, to assess the consequence of podocyte
Fig. 4. TGFBIp induces EMTmarkers in podocytes. Differentiatedmouse podocytes were treated with or without TGFBIp (5 ug/ml) for indicated time periods and cell lysates were
processed for immunoblotting or RNA isolation. A: Representative immunoblots showing the expression of EMT markers in TGFBIp treated podocytes. B: Densitometric
quantification of EMTmarkers normalized to tubulin. Expression of marker in untreated cells (0 h) considered as one fold. The results are shown asmean SE. (n¼ 3, *, P< 0.05).
C: Expression of EMT markers in TGFBIp treated podocytes as analyzed by RT-PCR with mRNA expression in control cells considered as one fold. The results are shown as
mean SE for n¼ 4 and P< 0.05.
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exposure to GH on its filtration barrier function, we employed
paracellular permeability assay that measures the rate of albumin
flux across the podocyte monolayer [Li et al., 2008; Kumar et al.,
2010]. For these experiments, podocytes were cultured on transwell
filters and exposed to GH or TGFBIp for 24 h and the influx of BSA
across the podocyte monolayer was measured. These results reveal
that both GH and TGFBIp increase albumin influx across the
podocytemonolayer (Fig. 5C). However, at the concentrations tested,
TGFBIp dependent increase in albumin efflux was greater than that
observed for GH (Fig. 5C). Increased permeability of podocytes to
albumin suggests reduced podocyte integrity upon treatment with
GH or TGFBIp.
GH ADMINISTRATION PROMOTES DECREASED PODOCYTE COUNT IN
WISTAR RAT KIDNEY
To validate the effect of GH on podocyte viability and EMT in vivo,
we injected rats with GH for 2 weeks and isolated glomeruli from
kidney. Upon immunoblotting analysis, we found that treatment
with GH resulted in increased ZEB2, N-cadherin and b-catenin, and
decreased E-cadherin expression (Fig. 6A). Interestingly, we also
found elevated expression of TGFBIp in GH treated rats (Fig. 6A). We
have also noticed increased p21 and decreased BCl2 in glomerular
fraction of GH treated rats (Fig. 6A). Decreased staining for
synaptopodin in glomeruli from GH treated rats revealed reduced
podocyte density (Fig. 6B). Hematoxylin and eosin (H&E) reveal
altered morphology of glomeruli in GH treated rats as evidenced by
thickening of basement membrane, mesangial sclerosis, and
interstitial infiltration (Fig. 6C). GH treated rats also showed
significantly decreased podocyte count compared with control rats
(Fig. 6D). We collected 24h urine from control and GH treated rats
and estimated albumin and creatinine. We found that albumin:
creatinine ratio was increased in rats treated with GH (Fig. 6E).
DISCUSSION
Our studies reveal that GH increases the levels of TGFBIp, an
extracellular matrix protein in podocytes. Both, GH and TGFBIp
induced apoptosis and EMT in podocytes and altered podocyte
permselectivity. Furthermore, we show that chronic administration
of GH to rats results in increased expression of TGFBIp and induction
of EMT in the glomerulus with concomitant decrease in the podocyte
count and proteinuria. These observations support a role for
increased GH levels, and GH-dependent increase in TGFBIp in the
causation of podocyte depletion and albuminuria in Type1 diabetes.
Podocyte number and integrity is critical for the maintenance of
normal glomerular filtration [Anil Kumar et al., 2014]. Proteinuria is
a hallmark of DN and studies have indicated that decreased podocyte
Fig. 5. GH and TGFBIp induces podocytemigration and alters permeability. Differentiatedmouse podocytes were grown under nonpermissive conditions as described inmethods
section and scratched in “þ” shape with a sterile yellow pipette tip. Following washing cells were treated with or without GH (500 ng/ml) or TGFBIp (5mg/ml) for 2 h. A: A
representative images of podocytes treated with or without GH/TGFBIp for 2 h. B:% area covered with cells after treating damaged cells with GH or TGFBIp for 2 h whereas area of
original wound is considered a 100%. C: Differentiatedmouse podocytes (MPC-5 cells) were grown under nonpermissive conditions as a monolayer and treated with GH (500 ng/
ml) or TGFBIp (5mg/ml) for 24 h, and albumin permeability across the podocytemonolayer was determined at 1, 2, and 4 h following the 24 h exposure to GH or TGFBIp. Error bars
indicate mean SE; n¼ 4.
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count is a key feature of DN. Circulating levels of GH are elevated in
type1 diabetes and elevated GH is one of the factors implicated in the
pathogenesis of DN. In type 1 diabetes, insulin deficiency results in
impaired hepatic IGF-1 production, which via negative feedback
mechanism stimulate pituitary gland to secrete more GH, thus
resulting in a higher circulatory levels of GH in diabetic patients
[Edge et al., 1990]. GH excess in both humans and in transgenic
animal models is characterized by significant structural and
functional changes in the kidney [Kumar et al., 2011]. Analogously,
states of GH deficiency or ablation of GH receptor (GHR) or its
activity confer a protective effect against DN [Kumar et al., 2011]. An
earlier study from our group revealed that podocytes express GHR
and respond to GH by activation of JAK/STAT signaling [Reddy
et al., 2007]. It was also demonstrated that podocytes respond to GH
by inducing expression of ZEB2, a transcription factor that mediates
EMT [Kumar et al., 2010]. However, the molecular mediator of GH0s
action on podocytes is not known. Therefore, we studied the effect of
GH on expression profile of extracellular matrix and adhesion
molecules and identified increased expression and extracellular
secretion of TGFBIp in GH treated podocytes.
TGFBIp was first identified in an A549 (lung adenocarcinoma) cell
line treated with TGF-b [Skonier et al., 1992]. TGFBIp is a secretory
protein of 68 kDa with an N-terminal secretory signal sequence, four
“Fas-1-like” domains homologous to Drosophila fasciclin and a C-
terminal “arginine-glycine-aspartate” (RGD) motif. TGFBIp interacts
with various extracellular matrix proteins to promote attachment,
migration, proliferation, and differentiation in a wide range of cells
by interacting with integrins via the RGD motif [Thapa et al., 2005].
Hence, TGFBIp has also been termed as RGD-collagen associated
protein (RGD-CAP). TGFBIp is expressed in a wide variety of tissues
including cornea, skin, tendon, endometrium and, kidney [Ween
et al., 2012]. TGFBIpmutations have been linked to corneal epithelial
and stromal dystrophies [Kannabiran and Klintworth, 2006]. The
physiological function of TGFBIp is postulated to involve cell-matrix
interactions to form an organized structure that supports normal cell
morphogenesis.
Our results indicate that GH stimulates TGFBIp expression in
podocytes. Since interaction between podocytes and GBM is critical
for normal renal function, aberrant expression of TGFBIp is expected
to exert a deleterious effect on the podocytes and result in impaired
glomerular filtration. Further, our studies reveal that treating
podocytes with TGFBIp results in both apoptosis and EMT, thus,
results in podocytopathy. Increased expression of TGFBIp has been
reported in Type 1 DM model [Gilbert et al., 1998]. Placed in the
context of elevated GH levels in type 1 DM, the finding of increased
expression of TGFBIp in podocytes argues for a role for increased
Fig. 6. In vivo administration of GH induces EMT and podocyte depletion. A: Expression of EMT and apoptotic markers in glomeruli from rats treated with GH for 2 weeks. B:
Immunofluoresnce detection of synaptopodin expression in control and GH treated rat glomeruli C: H&E staining of control and GH treated rat glomeruli. Increased thickening of
basement membrane (arrows), mesangial sclerosis and interstitial infiltration (*) was noticed in GH treated rats. D: Number of podocytes per glomeruli from control and GH
injected rats were counted fromWT-1 stained paraffin sections from control and GH-treated rats. E: Urinary albumin/creatinine ratio was measured from urine collected for 24 h
from control and GH treated rats. Error bars indicate mean SE (n¼ 6, *denotes P< 0.05).
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GH-dependent TGFBIp expression in the pathogenesis of podocyte
injury in DM.
In summary, our studies indicate that GH induced apoptosis and
EMT in part mediated by GH-dependent increase in TGFBIp
expression. We did not find any significant increase in IGF-1
expression in both GH treated podocytes and glomerular preparation
from GH injected rats (data not shown). Earlier studies also reported
that there was no increase in renal IGF-1 in GH injected rats [Landau
et al., 2003] and in mice transgenic for GH [Doi et al., 1990]. Taken
together, the data suggest that the deleterious effect of GH on renal
function is independent of IGF-1. The present study adds support for a
role for increased circulating levels of GH in the pathogenesis of DN in
type 1 DM. We speculate that blockade of TGFBIp could be a novel
approach to prevent podocyte damage and disease progression in DN.
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